Cargando…

Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT–IKK/STAT3 Axis

Aim: Inflammation and fibrosis have been shown to be critical factors in heart failure (HF) progression. Calycosin (Cal) is the major active component of Astragalus mongholicus Bunge and has been reported to have therapeutic effects on the cardiac dysfunction after myocardial infarction. However, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoping, Li, Weili, Zhang, Yawen, Sun, Qianbin, Cao, Jing, Tan, NanNan, Yang, Shuangjie, Lu, Linghui, Zhang, Qian, Wei, Peng, Ma, Xiao, Wang, Wei, Wang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899514/
https://www.ncbi.nlm.nih.gov/pubmed/35264961
http://dx.doi.org/10.3389/fphar.2022.828061
_version_ 1784663934956994560
author Wang, Xiaoping
Li, Weili
Zhang, Yawen
Sun, Qianbin
Cao, Jing
Tan, NanNan
Yang, Shuangjie
Lu, Linghui
Zhang, Qian
Wei, Peng
Ma, Xiao
Wang, Wei
Wang, Yong
author_facet Wang, Xiaoping
Li, Weili
Zhang, Yawen
Sun, Qianbin
Cao, Jing
Tan, NanNan
Yang, Shuangjie
Lu, Linghui
Zhang, Qian
Wei, Peng
Ma, Xiao
Wang, Wei
Wang, Yong
author_sort Wang, Xiaoping
collection PubMed
description Aim: Inflammation and fibrosis have been shown to be critical factors in heart failure (HF) progression. Calycosin (Cal) is the major active component of Astragalus mongholicus Bunge and has been reported to have therapeutic effects on the cardiac dysfunction after myocardial infarction. However, whether Cal could ameliorate myocardial infarction (MI)-induced inflammation and fibrosis and precise mechanisms remain uncertain. The aim of this study is to explore the role of Cal in HF and to clarify the underlying mechanisms. Methods: For in vivo experiments, rats underwent left anterior descending artery ligation for heart failure model, and the cardioprotective effects of Cal were measured by echocardiographic assessment and histological examination. RNA-seq approach was applied to explore potential differential genes and pathways. For further mechanistic study, proinflammatory-conditioned media (conditioned media)-induced H9C2 cell injury model and TGFβ-stimulated cardiac fibroblast model were applied to determine the regulatory mechanisms of Cal. Results: In the in vivo experiments, echocardiography results showed that Cal significantly improved heart function. GO and reactome enrichment revealed that inflammation and fibrosis pathways are involved in the Cal-treated group. KEGG enrichment indicated that the PI3K–AKT pathway is enriched in the Cal-treated group. Further experiments proved that Cal alleviated cardiomyocyte inflammatory responses evidenced by downregulating the expressions of phosphorylated IκB kinase α/β (p-IKKα/β), phosphorylated nuclear factor kapa B (p-NFκB), and tumor necrosis factor α (TNFα). Besides, Cal effectively attenuated cardiac fibrosis through the inhibitions of expressions and depositions of collagen I and collagen III. In the in vitro experiments, the phosphatidylinositol three kinase (PI3K) inhibitor LY294002 could abrogate the anti-inflammation and antifibrosis therapeutic effects of Cal, demonstrating that the cardioprotective effects of Cal were mediated through upregulations of PI3K and serine/threonine kinase (AKT). Conclusion: Cal inhibited inflammation and fibrosis via activation of the PI3K–AKT pathway in H9C2 cells, fibroblasts, and heart failure in postacute myocardial infarction rats.
format Online
Article
Text
id pubmed-8899514
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88995142022-03-08 Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT–IKK/STAT3 Axis Wang, Xiaoping Li, Weili Zhang, Yawen Sun, Qianbin Cao, Jing Tan, NanNan Yang, Shuangjie Lu, Linghui Zhang, Qian Wei, Peng Ma, Xiao Wang, Wei Wang, Yong Front Pharmacol Pharmacology Aim: Inflammation and fibrosis have been shown to be critical factors in heart failure (HF) progression. Calycosin (Cal) is the major active component of Astragalus mongholicus Bunge and has been reported to have therapeutic effects on the cardiac dysfunction after myocardial infarction. However, whether Cal could ameliorate myocardial infarction (MI)-induced inflammation and fibrosis and precise mechanisms remain uncertain. The aim of this study is to explore the role of Cal in HF and to clarify the underlying mechanisms. Methods: For in vivo experiments, rats underwent left anterior descending artery ligation for heart failure model, and the cardioprotective effects of Cal were measured by echocardiographic assessment and histological examination. RNA-seq approach was applied to explore potential differential genes and pathways. For further mechanistic study, proinflammatory-conditioned media (conditioned media)-induced H9C2 cell injury model and TGFβ-stimulated cardiac fibroblast model were applied to determine the regulatory mechanisms of Cal. Results: In the in vivo experiments, echocardiography results showed that Cal significantly improved heart function. GO and reactome enrichment revealed that inflammation and fibrosis pathways are involved in the Cal-treated group. KEGG enrichment indicated that the PI3K–AKT pathway is enriched in the Cal-treated group. Further experiments proved that Cal alleviated cardiomyocyte inflammatory responses evidenced by downregulating the expressions of phosphorylated IκB kinase α/β (p-IKKα/β), phosphorylated nuclear factor kapa B (p-NFκB), and tumor necrosis factor α (TNFα). Besides, Cal effectively attenuated cardiac fibrosis through the inhibitions of expressions and depositions of collagen I and collagen III. In the in vitro experiments, the phosphatidylinositol three kinase (PI3K) inhibitor LY294002 could abrogate the anti-inflammation and antifibrosis therapeutic effects of Cal, demonstrating that the cardioprotective effects of Cal were mediated through upregulations of PI3K and serine/threonine kinase (AKT). Conclusion: Cal inhibited inflammation and fibrosis via activation of the PI3K–AKT pathway in H9C2 cells, fibroblasts, and heart failure in postacute myocardial infarction rats. Frontiers Media S.A. 2022-02-21 /pmc/articles/PMC8899514/ /pubmed/35264961 http://dx.doi.org/10.3389/fphar.2022.828061 Text en Copyright © 2022 Wang, Li, Zhang, Sun, Cao, Tan, Yang, Lu, Zhang, Wei, Ma, Wang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Xiaoping
Li, Weili
Zhang, Yawen
Sun, Qianbin
Cao, Jing
Tan, NanNan
Yang, Shuangjie
Lu, Linghui
Zhang, Qian
Wei, Peng
Ma, Xiao
Wang, Wei
Wang, Yong
Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT–IKK/STAT3 Axis
title Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT–IKK/STAT3 Axis
title_full Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT–IKK/STAT3 Axis
title_fullStr Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT–IKK/STAT3 Axis
title_full_unstemmed Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT–IKK/STAT3 Axis
title_short Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT–IKK/STAT3 Axis
title_sort calycosin as a novel pi3k activator reduces inflammation and fibrosis in heart failure through akt–ikk/stat3 axis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899514/
https://www.ncbi.nlm.nih.gov/pubmed/35264961
http://dx.doi.org/10.3389/fphar.2022.828061
work_keys_str_mv AT wangxiaoping calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT liweili calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT zhangyawen calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT sunqianbin calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT caojing calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT tannannan calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT yangshuangjie calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT lulinghui calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT zhangqian calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT weipeng calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT maxiao calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT wangwei calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis
AT wangyong calycosinasanovelpi3kactivatorreducesinflammationandfibrosisinheartfailurethroughaktikkstat3axis